A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas

Journal of Thoracic Oncology

Volumn 6, Issue 10, 2011, Pages 1649-1657

  Sterlacci, William ^a   Tzankov, Alexandar ^b   Veits, Lothar ^a   Zelger, Bettina ^a   Bihl, Michel P ^b   Foerster, Anja ^b   Augustin, Florian ^a   Fiegl, Michael ^c   Savic, Spasenija ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Deletion; Expression; Hypermethylation; Nonsmall cell lung cancer; p16

Indexed keywords

PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DNA METHYLATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYROSEQUENCING; TISSUE MICROARRAY;

EID: 80052960976     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182295745     Document Type: Article

References (28)

1. Singhal S, Vachani A, Antin-Ozerkis D, et al. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005;11:3974-3986. (Pubitemid 40791561)
2. Panani AD, Maliaga K, Babanaraki A, et al. Numerical abnormalities of chromosome 9 and p16CDKN2A gene deletion detected by FISH in non-small cell lung cancer. Anticancer Res 2009;29:4483-4487.
3. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995;11:210-212.
4. Paulsen M, Ferguson-Smith AC. DNA methylation in genomic imprinting, development, and disease. J Pathol 2001;195:97-110.
5. Gray SG, Eriksson T, Ekström TJ. Methylation, gene expression and the chromatin connection in cancer. Int J Mol Med 1999;4:333-350.
6. Hong YS, Roh MS, Kim NY, et al. Hypermethylation of p16INK4a in Korean non-small cell lung cancer patients. J Korean Med Sci 2007; 22(Suppl):S32-S37.
7. Guzman LM, Koriyama C, Akiba S, et al. High frequency of p16 promoter methylation in non-small cell lung carcinomas from Chile. Biol Res 2007;40:365-372. (Pubitemid 351493262)
8. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-3344.
9. Vigil CE, Martin-Santos T, Garcia-Manero G. Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Des Devel Ther 2010; 4:221-229.
10. Juergens RA, Vendetti F, Coleman B, et al. Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced cancer (NSCLC). J Clin Oncol 2009;27(Suppl):15s (abstract 8055).
11. Taga S, Osaki T, Ohgami A, et al. Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma. Cancer 1997;80:389-395.
12. Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001;34:207-218. (Pubitemid 33010796)
13. Esposito V, Baldi A, Tonini G, et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol 2004;57:58-63. (Pubitemid 38091312)
14. Huang CI, Taki T, Higashiyama M, et al. p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung. Br J Cancer 2000;82:374-380. (Pubitemid 30045384)
15. Cheng YL, Lee SC, Harn HJ, et al. Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer. Eur J Cardiothorac Surg 2003;23:221-228.
16. Travis W, Brambilla E, Müller-Hermelink H, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARCPres, 2004.
17. Sterlacci W, Fiegl M, Hilbe W, et al. Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch 2009;455:125-132.
18. Sterlacci W, Tzankov A, Veits L, et al. The prognostic impact of sex on surgically resected non-small cell lung cancer depends on clinicopathological characteristics. Am J Clin Pathol 2011;135:611-618.
19. Fiegl M, Hilbe W, Auberger J, et al. Twelve-year retrospective analysis of lung cancer-The TYROL Study: Daily routine in 1,424 patients (1995-2006). J Clin Oncol 2008;26:abstract 19063.
20. Hilbe W, Aigner K, Dittrich C, et al. Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms. Wien Klin Wochenschr 2007;119:259-266. (Pubitemid 46895797)
21. Sterlacci W, Fiegl M, Hilbe W, et al. Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients. J Thorac Oncol 2010;5:1325-1336.
22. Tzankov A, Zlobec I, Went P, et al. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 2010; 51:199-212.
23. Myong NH. Cyclin D1 overexpression, p16 loss, and pRb inactivation play a key role in pulmonary carcinogenesis and have a prognostic implication for the long-term survival in non-small cell lung carcinoma patients. Cancer Res Treat 2008;40:45-52.
24. Kawabuchi B, Moriyama S, Hironaka M, et al. p16 inactivation in small-sized lung adenocarcinoma: its association with poor prognosis. Int J Cancer 1999;84:49-53. (Pubitemid 29059108)
25. Gazzeri S, Gouyer V, Vourch C, et al. Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene 1998;16:497-504. (Pubitemid 28062077)
26. Miyagi J, Tsuhako K, Kinjo T, et al. Recent striking changes in histological differentiation and rate of human papillomavirus infection in squamous cell carcinoma of the lung in Okinawa, a subtropical island in southern Japan. J Clin Pathol 2000;53:676-684.
27. Hilbe W, Dirnhofer S, Greil R, et al. Biomarkers in non-small cell lung cancer prevention. Eur J Cancer Prev 2004;13:425-436. (Pubitemid 39336608)
28. Kurkjian C, Kummar S, Murgo AJ. DNA methylation: its role in cancer development and therapy. Curr Probl Cancer 2008;32:187-235.